NASDAQ · PHAT
Phathom Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for PHAT has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Dec 2026 | $0.07 | $0.07 | $0.07 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Fintel · Zacks- RTTNews · 5 h agoPhathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook(RTTNews) – Phathom Pharmaceuticals, Inc. (PHAT) reported third-quarter 2026 net revenues of $84.7 million, up 71% from $49.5 million in the prior-year quarter, driven by continued growth in prescriptions for VOQUEZNA, its treatment for gastroesophageal reflux disease (GERD).
- The Motley Fool · 6 h agoPhathom (PHAT) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · 7 h agoPhathom Pharmaceuticals Reports Q3 2026 Net Revenues of $84.7 millionPhathom Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, with net revenues of $84.7 million, representing an increase compared to $49.5 million for third quarter 2025. The company reported a net loss of $13.9 million for the thi
- Zacks · Oct 29, 7:35 AM EDTPhathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue EstimatesPhathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Oct 26, 6:23 AM EDTFDA Establishes Public Docket FDA-2026-N-13038 Following Challenge to VOQUEZNA ExclusivityPhathom Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has established a public docket, Docket No. FDA-2026-N-13038, to solicit comments on legal and regulatory questions. These questions were raised by BDR Pharmaceuticals, Intl. Pvt. Ltd., an abbrevia
- RTTNews · Oct 26, 5:40 AM EDTPhathom Defends VOQUEZNA Exclusivity As FDA Seeks Comments On Generic Drug Dispute; Stock Down(RTTNews) – Phathom Pharmaceuticals, Inc. (PHAT) said Monday the U.S. Food and Drug Administration (FDA) opened a public docket seeking comments on legal and regulatory issues raised in BDR Pharmaceuticals International's lawsuit against the agency.
- RTTNews · Oct 26, 5:08 AM EDTPhathom Pharma To Intervene In Litigation Filed By BDR(RTTNews) – Phathom Pharmaceuticals (PHAT) announced the FDA's establishment of a public docket to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application referencing VOQUEZNA tablets, BDR Pharmaceuticals
- Fintel · Oct 23, 8:08 PM EDTPhathom Pharmaceuticals, Inc. Announces Lawsuit Challenging VOQUEZNA Exclusivity Through May 3, 2032On October 23, 2026, Phathom Pharmaceuticals, Inc. announced that BDR Pharmaceuticals International Pvt. Ltd. has filed suit against the U.S. Food and Drug Administration and related Federal Defendants in the United States District Court for the District of Columbia. The lawsuit
- RTTNews · Oct 23, 6:37 AM EDTPhathom Pharmaceuticals Reports BDR Lawsuit Challenging VOQUEZNA Exclusivity(RTTNews) – Phathom Pharmaceuticals (PHAT) announced that BDR Pharmaceuticals International Pvt. Ltd. has filed a lawsuit against the U.S. Food and Drug Administration (FDA) and related federal defendants, challenging the agency's alleged refusal to accept an abbreviated new drug
- RTTNews · Oct 23, 5:30 AM EDTPhathom Says BDR Pharmaceuticals Sues FDA Over VOQUEZNA Exclusivity(RTTNews) – Biopharmaceutical company Phathom Pharmaceuticals, Inc. (PHAT) announced on Friday that Mumbai, India-based BDR Pharmaceuticals International Pvt. Ltd. has filed a lawsuit against the U.S. Food and Drug Administration or FDA, challenging the agency's decision to grant
- RTTNews · Oct 12, 9:36 AM EDTPhathom's VOQUEZNA Data Point To Potential Long-Term Savings In GERD Care; Stock Down(RTTNews) – Phathom Pharmaceuticals (PHAT), a biopharmaceutical company focused on gastrointestinal diseases, presented new cost-effectiveness and clinical data for VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting.
- RTTNews · Oct 12, 9:27 AM EDTPhathom Pharmaceuticals Highlights VOQUEZNA Data At ACG 2026(RTTNews) – Phathom Pharmaceuticals (PHAT) presented new cost-effectiveness and clinical data for VOQUEZNA (vonoprazan) at the American College of Gastroenterology 2026 Annual Scientific Meeting.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Phathom Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.